Trial reportFrontiers in immunology2020
Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis.
Open access · goldAbstract readClinical Trial
In one paragraph
Trial report in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Pooled it
- Diagnostic accuracy of antineutrophil cytoplasmic antibodies (ANCA) in predicting relapses of ANCA-associated vasculitis: systematic review and meta-analysis.Rheumatology international · 2023Pooled it
- Towards a proteomic plasma biomarker panel for diagnosing vasculitis remission.Nature communications · 2026Article
- Diagnostic Performance of ANCA IIF in Relation to PR3 and MPO Antibodies: Impact of Formalin Reactivity in a Large Real-World Cohort.Diagnostics (Basel, Switzerland) · 2026Article
- A 3D Surface Plot for the Effective Visualization of Specific Serum Antibody Binding Properties.Antibodies (Basel, Switzerland) · 2025Article
- Review
- History of antineutrophil cytoplasmic autoantibodies : Milestones in rheumatology.Zeitschrift fur Rheumatologie · 2025Review
- New Biomarkers for Systemic Necrotizing Vasculitides.Journal of clinical medicine · 2024Review
- The effect of achieving serological remission on subsequent risk of relapse, end-stage renal disease and mortality in ANCA-associated vasculitis: a target trial emulation study.Annals of the rheumatic diseases · 2022Article
- Type of ANCA May Be Indispensable in Distinguishing Subphenotypes of Different Clinical Entities in ANCA-Associated Vasculitis.Life (Basel, Switzerland) · 2022Review
- Precision medicine for the treatment of glomerulonephritis: a bold goal but not yet a transformative achievement.Clinical kidney journal · 2022Review
- Pathogenicity of Proteinase 3-Anti-Neutrophil Cytoplasmic Antibody in Granulomatosis With Polyangiitis: Implications as Biomarker and Future Therapies.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 10 institutions in 2 countries.
Gwen E ThompsonEssentia Health, Division of Pulmonary and Critical Care, Fargo, ND, United States.
Lynn A FussnerDivision of Pulmonary, Critical Care, and Sleep Medicine, The Ohio State University, Columbus, OH, United States.
Amber M HummelMayo Clinic and Mayo Foundation for Research and Education, Rochester, MN, United States.
Darrell R SchroederMayo Clinic and Mayo Foundation for Research and Education, Rochester, MN, United States.
Francisco SilvaDepartment of Rheumatology, Facultad de Medicina Clínica Alemana Universidad del Desarrollo, Santiago, Chile.
Melissa R SnyderMayo Clinic and Mayo Foundation for Research and Education, Rochester, MN, United States.
Carol A LangfordCleveland Clinic, Division of Rheumatology, Cleveland, OH, United States.
Peter A MerkelDivision of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Paul A MonachDivision of Rheumatology, Brigham and Women's Hospital, Boston, MA, United States.
Philip SeoDivision of Rheumatology, Johns Hopkins University, Baltimore, MD, United States.
Robert F SpieraDivision of Rheumatology, Hospital for Special Surgery, New York, NY, United States.
E William St ClairDivision of Rheumatology, Duke University, Durham, NC, United States.
John H StoneDivision of Rheumatology, Massachusetts General Hospital, Boston, MA, United States.
Ulrich SpecksMayo Clinic and Mayo Foundation for Research and Education, Rochester, MN, United States.
Mayo Clinic · USBrigham and Women's Hospital · USCleveland Clinic · USDuke University · USHospital for Special Surgery · USJohns Hopkins University · USMassachusetts General Hospital · USThe Ohio State University · USUniversidad del Desarrollo · CLUniversity of Pennsylvania · US
Funding
Immune Tolerance Network: Type 1 diabetesN01AI15416 · NIAID · UNIVERSITY OF SAN FRANCISCO · PI BLUESTONE, JEFFREY · 2007 to 2013
$276.6MInstitute for Clinical and Translational Research (UL1)UL1RR025005 · NCRR · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2007 to 2011
$75.8MMAYO CLINIC CENTER FOR TRANSLATIONAL SCIENCE ACTIVITIESUL1RR024150 · NCRR · MAYO CLINIC ROCHESTER · PI RIZZA, ROBERT A. · 2006 to 2011
$66.4MMayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2MYOGA INDUCED CHANGES IN BRAIN GABA LEVELSM01RR000533 · NCRR · BOSTON UNIVERSITY MEDICAL CAMPUS · PI HOLICK, MICHAEL F. · 1985 to 2008
$19.4MCTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025771 · NCRR · BOSTON UNIVERSITY MEDICAL CAMPUS · PI CENTER, DAVID M. · 2008 to 2011
$17.6MDevelopment of an ANCA-Vasculitis Index of Damage (AVID)K23AR052820 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI SEO, PHILIP · 2005 to 2009
$661kStudies in Scleroderma and Cystic Fibrosis OsteoporosisK24AR002224 · NIAMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI MERKEL, PETER A · 2001 to 2005
$609kTranslational Research in Systemic VasculitisK24AR049185 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI STONE, JOHN H · 2003 to 2006
$351kIMMUNE TOLERANCE NETWORK-266015416-266015416N01AI015416 · NIAID · REGENTS OF THE UNIVERSITY OF C · PI BLUESTONE, JEFFREY A · 2002 to 2006
–NCATS NIH HHS UL1 TR000135NCRR NIH HHS M01 RR000533NCRR NIH HHS UL1 RR024150NCRR NIH HHS UL1 RR025005NCRR NIH HHS UL1 RR025771NIAID NIH HHS N01 AI015416NIAID NIH HHS N01AI15416NIAMS NIH HHS K23 AR052820NIAMS NIH HHS K24 AR002224NIAMS NIH HHS K24 AR049185
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antibodies, Antineutrophil CytoplasmicAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisBiomarkersCyclophosphamideHumansImmunoassayImmunosuppressive AgentsMyeloblastinRituximabSerologic TestsAntibodies, Antineutrophil CytoplasmicBiomarkersCyclophosphamideImmunosuppressive AgentsMyeloblastinRituximabANCA-associated vasculitisbiomarkerPR3-ANCArelapse activityremission
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.